Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Lymph Node Imaging in Patients with Primary Breast Cancer: Concurrent Diagnostic Tools.

Marino MA, Avendano D, Zapata P, Riedl CC, Pinker K.

Oncologist. 2019 Oct 14. pii: theoncologist.2019-0427. doi: 10.1634/theoncologist.2019-0427. [Epub ahead of print]

PMID:
31611331
2.

Diffusion-weighted MRI for Unenhanced Breast Cancer Screening.

Amornsiripanitch N, Bickelhaupt S, Shin HJ, Dang M, Rahbar H, Pinker K, Partridge SC.

Radiology. 2019 Oct 8:182789. doi: 10.1148/radiol.2019182789. [Epub ahead of print]

PMID:
31592734
3.

Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results.

Leithner D, Horvat JV, Marino MA, Bernard-Davila B, Jochelson MS, Ochoa-Albiztegui RE, Martinez DF, Morris EA, Thakur S, Pinker K.

Breast Cancer Res. 2019 Sep 12;21(1):106. doi: 10.1186/s13058-019-1187-z.

4.

Contrast-Enhanced Mammography and Radiomics Analysis for Noninvasive Breast Cancer Characterization: Initial Results.

Marino MA, Pinker K, Leithner D, Sung J, Avendano D, Morris EA, Jochelson M.

Mol Imaging Biol. 2019 Aug 28. doi: 10.1007/s11307-019-01423-5. [Epub ahead of print]

PMID:
31463822
5.

Mammographic screening in male patients at high risk for breast cancer: is it worth it?

Marino MA, Gucalp A, Leithner D, Keating D, Avendano D, Bernard-Davila B, Morris EA, Pinker K, Jochelson MS.

Breast Cancer Res Treat. 2019 Oct;177(3):705-711. doi: 10.1007/s10549-019-05338-1. Epub 2019 Jul 6.

PMID:
31280425
6.

Multiparametric 18F-FDG PET-MRI of the breast: are there differences in imaging biomarkers of contralateral healthy tissue between patients with and without breast cancer?

Leithner D, Helbich TH, Bernard-Davila B, Marino MA, Avendano D, Martinez DF, Jochelson M, Kapetas P, Baltzer PA, Haug A, Hacker M, Tanyildizi Y, Morris EA, Pinker K.

J Nucl Med. 2019 Jun 28. pii: jnumed.119.230003. doi: 10.2967/jnumed.119.230003. [Epub ahead of print]

PMID:
31253745
7.

Is Background Parenchymal Enhancement an Important Risk Factor for Breast Cancer Development in Women with Increased Risk?

Mann RM, Pinker K.

Radiology. 2019 Sep;292(3):562-563. doi: 10.1148/radiol.2019191164. Epub 2019 Jun 25. No abstract available.

PMID:
31237810
8.

Radiomic Signatures Derived from Diffusion-Weighted Imaging for the Assessment of Breast Cancer Receptor Status and Molecular Subtypes.

Leithner D, Bernard-Davila B, Martinez DF, Horvat JV, Jochelson MS, Marino MA, Avendano D, Ochoa-Albiztegui RE, Sutton EJ, Morris EA, Thakur SB, Pinker K.

Mol Imaging Biol. 2019 Jun 17. doi: 10.1007/s11307-019-01383-w. [Epub ahead of print]

PMID:
31209778
9.

A multiparametric [18F]FDG PET/MRI diagnostic model including imaging biomarkers of the tumor and contralateral healthy breast tissue aids breast cancer diagnosis.

Leithner D, Horvat JV, Bernard-Davila B, Helbich TH, Ochoa-Albiztegui RE, Martinez DF, Zhang M, Thakur SB, Wengert GJ, Staudenherz A, Jochelson MS, Morris EA, Baltzer PAT, Clauser P, Kapetas P, Pinker K.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1878-1888. doi: 10.1007/s00259-019-04331-6. Epub 2019 Jun 13.

10.

MRI evaluation of axillary and intramammary lymph nodes in the postoperative period.

Horvat JV, Morris EA, Bernard-Davila B, Martinez DF, Leithner D, Ochoa-Albiztegui RE, Thakur SB, Pinker K.

Breast J. 2019 Sep;25(5):916-921. doi: 10.1111/tbj.13355. Epub 2019 Jun 7.

11.

Intra- and inter-observer variability in dependence of T1-time correction for common dynamic contrast enhanced MRI parameters in prostate cancer patients.

Daniel M, Polanec SH, Wengert G, Clauser P, Pinker K, Helbich TH, Georg D, Baltzer PAT.

Eur J Radiol. 2019 Jul;116:27-33. doi: 10.1016/j.ejrad.2019.04.015. Epub 2019 Apr 23.

PMID:
31153570
12.

Correction to: Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

Rageth CJ, O'Flynn EAM, Pinker K, Kubik-Huch RA, Mundinger A, Decker T, Tausch C, Dammann F, Baltzer PA, Fallenberg EM, Foschini MP, Dellas S, Knauer M, Malhaire C, Sonnenschein M, Boos A, Morris E, Varga Z.

Breast Cancer Res Treat. 2019 Jul;176(2):481-482. doi: 10.1007/s10549-019-05287-9.

13.

Diffusion-Weighted MRI of Breast Cancer: Improved Lesion Visibility and Image Quality Using Synthetic b-Values.

Bickel H, Polanec SH, Wengert G, Pinker K, Bogner W, Helbich TH, Baltzer PA.

J Magn Reson Imaging. 2019 May 28. doi: 10.1002/jmri.26809. [Epub ahead of print]

PMID:
31136044
14.

Automatic segmentation and classification of breast lesions through identification of informative multiparametric PET/MRI features.

Vogl WD, Pinker K, Helbich TH, Bickel H, Grabner G, Bogner W, Gruber S, Bago-Horvath Z, Dubsky P, Langs G.

Eur Radiol Exp. 2019 Apr 27;3(1):18. doi: 10.1186/s41747-019-0096-3.

15.

[Contrast agent-free breast MRI : Advantages and potential disadvantages].

Baltzer PAT, Kapetas P, Sodano C, Dietzel M, Pinker K, Helbich TH, Clauser P.

Radiologe. 2019 Jun;59(6):510-516. doi: 10.1007/s00117-019-0524-7. Review. German.

PMID:
31001650
16.

Can we predict lesion detection rates in second-look ultrasound of MRI-detected breast lesions? A systematic analysis.

Bumberger A, Clauser P, Kolta M, Kapetas P, Bernathova M, Helbich TH, Pinker K, Baltzer PA.

Eur J Radiol. 2019 Apr;113:96-100. doi: 10.1016/j.ejrad.2019.02.008. Epub 2019 Feb 11.

PMID:
30927966
17.

Proton MR spectroscopy in the breast: Technical innovations and clinical applications.

Fardanesh R, Marino MA, Avendano D, Leithner D, Pinker K, Thakur SB.

J Magn Reson Imaging. 2019 Oct;50(4):1033-1046. doi: 10.1002/jmri.26700. Epub 2019 Mar 7. Review.

PMID:
30848037
18.

Diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer.

Horvat JV, Bernard-Davila B, Helbich TH, Zhang M, Morris EA, Thakur SB, Ochoa-Albiztegui RE, Leithner D, Marino MA, Baltzer PA, Clauser P, Kapetas P, Bago-Horvath Z, Pinker K.

J Magn Reson Imaging. 2019 Sep;50(3):836-846. doi: 10.1002/jmri.26697. Epub 2019 Feb 27.

19.

Sequential [18F]FDG-[18F]FMISO PET and Multiparametric MRI at 3T for Insights into Breast Cancer Heterogeneity and Correlation with Patient Outcomes: First Clinical Experience.

Andrzejewski P, Wengert G, Helbich TH, Magometschnigg H, Georg D, Hacker M, Baltzer P, Clauser P, Kapetas P, Georg P, Wadsak W, Pinker K.

Contrast Media Mol Imaging. 2019 Jan 8;2019:1307247. doi: 10.1155/2019/1307247. eCollection 2019.

20.

PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT.

Magometschnigg H, Pinker K, Helbich T, Brandstetter A, Rudas M, Nakuz T, Baltzer P, Wadsak W, Hacker M, Weber M, Dubsky P, Filipits M.

Mol Imaging Biol. 2019 Oct;21(5):991-1002. doi: 10.1007/s11307-018-01308-z.

PMID:
30652258
21.

Automated Detection and Segmentation of Nonmass-Enhancing Breast Tumors with Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

Illan IA, Ramirez J, Gorriz JM, Marino MA, Avendano D, Helbich T, Baltzer P, Pinker K, Meyer-Baese A.

Contrast Media Mol Imaging. 2018 Oct 24;2018:5308517. doi: 10.1155/2018/5308517. eCollection 2018.

22.

Quantitative Multiparametric Breast Ultrasound: Application of Contrast-Enhanced Ultrasound and Elastography Leads to an Improved Differentiation of Benign and Malignant Lesions.

Kapetas P, Clauser P, Woitek R, Wengert GJ, Lazar M, Pinker K, Helbich TH, Baltzer PAT.

Invest Radiol. 2019 May;54(5):257-264. doi: 10.1097/RLI.0000000000000543.

PMID:
30632985
23.

Quantitative in vivo proton MR spectroscopic assessment of lipid metabolism: Value for breast cancer diagnosis and prognosis.

Thakur SB, Horvat JV, Hancu I, Sutton OM, Bernard-Davila B, Weber M, Oh JH, Marino MA, Avendano D, Leithner D, Brennan S, Giri D, Manderski E, Morris EA, Pinker K.

J Magn Reson Imaging. 2019 Jul;50(1):239-249. doi: 10.1002/jmri.26622. Epub 2019 Jan 3.

PMID:
30605266
24.

Breast lesion detection and characterization with contrast-enhanced magnetic resonance imaging: Prospective randomized intraindividual comparison of gadoterate meglumine (0.15 mmol/kg) and gadobenate dimeglumine (0.075 mmol/kg) at 3T.

Clauser P, Helbich TH, Kapetas P, Pinker K, Bernathova M, Woitek R, Kaneider A, Baltzer PAT.

J Magn Reson Imaging. 2019 Apr;49(4):1157-1165. doi: 10.1002/jmri.26335. Epub 2018 Dec 15.

25.

Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

Rageth CJ, O'Flynn EAM, Pinker K, Kubik-Huch RA, Mundinger A, Decker T, Tausch C, Dammann F, Baltzer PA, Fallenberg EM, Foschini MP, Dellas S, Knauer M, Malhaire C, Sonnenschein M, Boos A, Morris E, Varga Z.

Breast Cancer Res Treat. 2019 Apr;174(2):279-296. doi: 10.1007/s10549-018-05071-1. Epub 2018 Nov 30. Review. Erratum in: Breast Cancer Res Treat. 2019 Jul;176(2):481-482.

26.

Development of a Non-invasive Assessment of Hypoxia and Neovascularization with Magnetic Resonance Imaging in Benign and Malignant Breast Tumors: Initial Results.

Stadlbauer A, Zimmermann M, Bennani-Baiti B, Helbich TH, Baltzer P, Clauser P, Kapetas P, Bago-Horvath Z, Pinker K.

Mol Imaging Biol. 2019 Aug;21(4):758-770. doi: 10.1007/s11307-018-1298-4.

PMID:
30478507
27.

Beyond Breast Density: Radiomic Phenotypes Enhance Assessment of Breast Cancer Risk.

Pinker K.

Radiology. 2019 Jan;290(1):50-51. doi: 10.1148/radiol.2018182296. Epub 2018 Oct 30. No abstract available.

PMID:
30375934
28.

Multiparametric MRI model with dynamic contrast-enhanced and diffusion-weighted imaging enables breast cancer diagnosis with high accuracy.

Zhang M, Horvat JV, Bernard-Davila B, Marino MA, Leithner D, Ochoa-Albiztegui RE, Helbich TH, Morris EA, Thakur S, Pinker K.

J Magn Reson Imaging. 2019 Mar;49(3):864-874. doi: 10.1002/jmri.26285. Epub 2018 Oct 30.

29.

Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.

Tahmassebi A, Wengert GJ, Helbich TH, Bago-Horvath Z, Alaei S, Bartsch R, Dubsky P, Baltzer P, Clauser P, Kapetas P, Morris EA, Meyer-Baese A, Pinker K.

Invest Radiol. 2019 Feb;54(2):110-117. doi: 10.1097/RLI.0000000000000518.

PMID:
30358693
30.

Density and tailored breast cancer screening: practice and prediction - an overview.

Wengert GJ, Helbich TH, Kapetas P, Baltzer PA, Pinker K.

Acta Radiol Open. 2018 Sep 17;7(9):2058460118791212. doi: 10.1177/2058460118791212. eCollection 2018 Sep.

31.

Abbreviated MRI of the Breast: Does It Provide Value?

Leithner D, Moy L, Morris EA, Marino MA, Helbich TH, Pinker K.

J Magn Reson Imaging. 2019 Jun;49(7):e85-e100. doi: 10.1002/jmri.26291. Epub 2018 Sep 8.

32.

Imaging Phenotypes in Women at High Risk for Breast Cancer on Mammography, Ultrasound, and Magnetic Resonance Imaging Using the Fifth Edition of the Breast Imaging Reporting and Data System.

Marino MA, Riedl CC, Bernathova M, Bernhart C, Baltzer PAT, Helbich TH, Pinker K.

Eur J Radiol. 2018 Sep;106:150-159. doi: 10.1016/j.ejrad.2018.07.026. Epub 2018 Jul 30.

PMID:
30150038
33.

Breast ultrasound: recommendations for information to women and referring physicians by the European Society of Breast Imaging.

Evans A, Trimboli RM, Athanasiou A, Balleyguier C, Baltzer PA, Bick U, Camps Herrero J, Clauser P, Colin C, Cornford E, Fallenberg EM, Fuchsjaeger MH, Gilbert FJ, Helbich TH, Kinkel K, Heywang-Köbrunner SH, Kuhl CK, Mann RM, Martincich L, Panizza P, Pediconi F, Pijnappel RM, Pinker K, Zackrisson S, Forrai G, Sardanelli F; European Society of Breast Imaging (EUSOBI) , with language review by Europa Donna–The European Breast Cancer Coalition.

Insights Imaging. 2018 Aug;9(4):449-461. doi: 10.1007/s13244-018-0636-z. Epub 2018 Aug 9.

34.

Quantitative Apparent Diffusion Coefficient Derived From Diffusion-Weighted Imaging Has the Potential to Avoid Unnecessary MRI-Guided Biopsies of mpMRI-Detected PI-RADS 4 and 5 Lesions.

Polanec SH, Helbich TH, Bickel H, Wengert GJ, Pinker K, Spick C, Clauser P, Susani M, Shariat S, Baltzer PAT.

Invest Radiol. 2018 Dec;53(12):736-741. doi: 10.1097/RLI.0000000000000498.

PMID:
29985792
35.

Imaging and the completion of the omics paradigm in breast cancer.

Leithner D, Horvat JV, Ochoa-Albiztegui RE, Thakur S, Wengert G, Morris EA, Helbich TH, Pinker K.

Radiologe. 2018 Nov;58(Suppl 1):7-13. doi: 10.1007/s00117-018-0409-1. Review.

36.

MRI-based quantification of residual fibroglandular tissue of the breast after conservative mastectomies.

Woitek R, Pfeiler G, Farr A, Kapetas P, Furtner J, Bernathova M, Schöpf V, Clauser P, Marino MA, Pinker K, Baltzer PA, Helbich TH.

Eur J Radiol. 2018 Jul;104:1-7. doi: 10.1016/j.ejrad.2018.04.028. Epub 2018 Apr 26.

PMID:
29857853
37.

Precision Medicine and Radiogenomics in Breast Cancer: New Approaches toward Diagnosis and Treatment.

Pinker K, Chin J, Melsaether AN, Morris EA, Moy L.

Radiology. 2018 Jun;287(3):732-747. doi: 10.1148/radiol.2018172171. Review.

PMID:
29782246
38.

Commentary ACOG Practice Bulletin July 2017: Breast Cancer Risk Assessment and Screening in Average-Risk Women.

Mango V, Bryce Y, Morris EA, Gianotti E, Pinker K.

Br J Radiol. 2018 Oct;91(1090):20170907. doi: 10.1259/bjr.20170907. Epub 2018 May 24.

39.

A Simple Ultrasound Based Classification Algorithm Allows Differentiation of Benign from Malignant Breast Lesions by Using Only Quantitative Parameters.

Kapetas P, Woitek R, Clauser P, Bernathova M, Pinker K, Helbich TH, Baltzer PA.

Mol Imaging Biol. 2018 Dec;20(6):1053-1060. doi: 10.1007/s11307-018-1187-x.

40.

Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Breast Cancer Detection as a Stand-Alone Parameter: Comparison With Dynamic Contrast-Enhanced and Multiparametric Magnetic Resonance Imaging.

Pinker K, Moy L, Sutton EJ, Mann RM, Weber M, Thakur SB, Jochelson MS, Bago-Horvath Z, Morris EA, Baltzer PA, Helbich TH.

Invest Radiol. 2018 Oct;53(10):587-595. doi: 10.1097/RLI.0000000000000465.

41.

Virtual Touch IQ elastography reduces unnecessary breast biopsies by applying quantitative "rule-in" and "rule-out" threshold values.

Kapetas P, Clauser P, Woitek R, Pinker K, Bernathova M, Helbich TH, Baltzer PA.

Sci Rep. 2018 Feb 26;8(1):3583. doi: 10.1038/s41598-018-22065-7.

42.

The frequency of missed breast cancers in women participating in a high-risk MRI screening program.

Vreemann S, Gubern-Merida A, Lardenoije S, Bult P, Karssemeijer N, Pinker K, Mann RM.

Breast Cancer Res Treat. 2018 Jun;169(2):323-331. doi: 10.1007/s10549-018-4688-z. Epub 2018 Jan 31.

43.

Apparent diffusion coefficient mapping using diffusion-weighted MRI: impact of background parenchymal enhancement, amount of fibroglandular tissue and menopausal status on breast cancer diagnosis.

Horvat JV, Durando M, Milans S, Patil S, Massler J, Gibbons G, Giri D, Pinker K, Morris EA, Thakur SB.

Eur Radiol. 2018 Jun;28(6):2516-2524. doi: 10.1007/s00330-017-5202-4. Epub 2018 Jan 12.

44.

Clinical role of breast MRI now and going forward.

Leithner D, Wengert GJ, Helbich TH, Thakur S, Ochoa-Albiztegui RE, Morris EA, Pinker K.

Clin Radiol. 2018 Aug;73(8):700-714. doi: 10.1016/j.crad.2017.10.021. Epub 2017 Dec 9. Review.

45.

Potential of Noncontrast Magnetic Resonance Imaging With Diffusion-Weighted Imaging in Characterization of Breast Lesions: Intraindividual Comparison With Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

Baltzer PAT, Bickel H, Spick C, Wengert G, Woitek R, Kapetas P, Clauser P, Helbich TH, Pinker K.

Invest Radiol. 2018 Apr;53(4):229-235. doi: 10.1097/RLI.0000000000000433.

PMID:
29190227
46.

A survey by the European Society of Breast Imaging on the utilisation of breast MRI in clinical practice.

Clauser P, Mann R, Athanasiou A, Prosch H, Pinker K, Dietzel M, Helbich TH, Fuchsjäger M, Camps-Herrero J, Sardanelli F, Forrai G, Baltzer PAT.

Eur Radiol. 2018 May;28(5):1909-1918. doi: 10.1007/s00330-017-5121-4. Epub 2017 Nov 22.

47.

Impact of hybrid PET/MR technology on multiparametric imaging and treatment response assessment of cervix cancer.

Daniel M, Andrzejewski P, Sturdza A, Majercakova K, Baltzer P, Pinker K, Wadsak W, Mitterhauser M, Pötter R, Georg P, Helbich T, Georg D.

Radiother Oncol. 2017 Dec;125(3):420-425. doi: 10.1016/j.radonc.2017.10.036. Epub 2017 Nov 15.

PMID:
29153465
48.

Comparison of screening CEDM and MRI for women at increased risk for breast cancer: A pilot study.

Jochelson MS, Pinker K, Dershaw DD, Hughes M, Gibbons GF, Rahbar K, Robson ME, Mangino DA, Goldman D, Moskowitz CS, Morris EA, Sung JS.

Eur J Radiol. 2017 Dec;97:37-43. doi: 10.1016/j.ejrad.2017.10.001. Epub 2017 Oct 7.

PMID:
29153365
49.

Background, current role, and potential applications of radiogenomics.

Pinker K, Shitano F, Sala E, Do RK, Young RJ, Wibmer AG, Hricak H, Sutton EJ, Morris EA.

J Magn Reson Imaging. 2018 Mar;47(3):604-620. doi: 10.1002/jmri.25870. Epub 2017 Nov 2. Review.

50.

Automated Semi-Quantitative Analysis of Breast MRI: Potential Imaging Biomarker for the Prediction of Tissue Response to Neoadjuvant Chemotherapy.

Dietzel M, Kaiser C, Pinker K, Wenkel E, Hammon M, Uder M, Bennani Baiti B, Clauser P, Schulz-Wendtland R, Baltzer P.

Breast Care (Basel). 2017 Sep;12(4):231-236. doi: 10.1159/000480226. Epub 2017 Aug 29.

Supplemental Content

Loading ...
Support Center